PR NEWSWIRE - Contenuti promozionali

DOYLESTOWN, Pa., Oct. 7, 2026 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will feature LACRIFILL® Canalicular Gel, a novel therapy for ocular surface control, during the American Academy of Ophthalmology Annual Meeting in New Orleans, LA, from October 9–12 and will ...

Exclusive partnership results in a user-centric, hydrocarbon-cooled centrifuge purpose-built for clinical trials – years ahead of upcoming F-gas regulatory changes in Europe and the U.S.

HONG KONG, Oct. 7, 2026 /PRNewswire/ -- ANTA Sports Products Limited, the world's leading multi-brand sportswear group ("ANTA Sports", stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the "ANTA Group" or the "Group"), today announced the completion of its acq...

More than 175 biotechs use pre-configured applications to streamline operations

VERONA, Italia, 7 ottobre 2026 /PRNewswire/ -- GONEO ha partecipato a Solar & Storage Live Italia 2026, in programma il 7 e 8 ottobre presso Veronafiere, a Verona, presentando soluzioni per l'accumulo di energia e la ricarica dei veicoli elettrici destinate ad applicazioni residenziali, commerciali e...

Il 96% delle PMI italiane intervistate* considera l'IA agentica importante per il futuro del business: dalla ricerca dei fornitori alla gestione della logistica, le aziende individuano applicazioni concrete per semplificare attività complesse.

VEVEY, Svizzera, 7 ottobre 2026 /PRNewswire/ -- Nestlé e l'NBA danno il via a una nuova partnership internazionale di marketing pluriennale, che renderà Milo, Nescau e Nesquik Partner Ufficiali dell'NBA.

Profilo aziendale, leadership del fondatore e piattaforma fintech Nova

New open source initiative integrates and builds a data platform and tools to accelerate grid planning and energy infrastructure deployments worldwide

xFusion will contribute its infrastructure expertise to open source communities across the Linux Foundation    

European organizations report strong returns from open source as AI adoption, regulation and technology sovereignty reshape software strategy

ORTEC advances AI-powered planning for more adaptive, resilient logistics operations.

SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.

DeepSights MCP, now generally available, connects an expert market intelligence AI to Microsoft Copilot, ChatGPT, Claude and custom agents, so everyday AI work draws on accurate, cited market evidence

LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetratio...

Bitmine detiene il 4,9% dell'offerta complessiva di ETH, pari a 122,1 milioni di token

WASHINGTON, Oct. 7, 2026 /PRNewswire/ -- The Sultan of Afar Ahmed Alimirah is calling for support for the United Nations and African Union's call for de-escalation and talks to promote peace in the Ethiopian homeland of the Afar. A statement entitled "This is Not Our War" details the plight of the Af...

ALTSTÄTTEN, Switzerland and BOSTON, Oct. 6, 2026 /PRNewswire/ -- icotec, the global leader in radiolucent implants for spine tumors and other complex spinal surgery patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) fo...

CAMBRIDGE, England, Oct. 6, 2026 /PRNewswire/ -- Cambridge Heartwear® Limited (www.camheartwear.com) has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for HeartSense®, the world's first medical-grade, multi-channel, portable, wirelessly charged ECG wearable s...

Live case showcases successful below-the-knee revascularization with two MOTIV® scaffolds; late-breaking analysis shows higher efficacy endpoint rates with MOTIV versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations